{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:47:16Z","timestamp":1783414036520,"version":"3.54.6"},"reference-count":93,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,2,18]],"date-time":"2023-02-18T00:00:00Z","timestamp":1676678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary liver cancer is the sixth most common cancer and the fourth leading cause of cancer-related death. Hepatocellular carcinoma (HCC) accounts for 75% of primary liver cancer cases, mostly on the basis of cirrhosis. However, the data and therapeutic options for the treatment of HCC in patients with decompensated cirrhosis are rather limited. This patient category is often considered to be in a terminal stage without the possibility of a specific treatment except liver transplantation, which is restricted by several criteria and liver donor shortages. Systemic treatments may provide a solution for patients with Child Pugh class B or C since they are less invasive. Although most of the existing trials have excluded patients with decompensated cirrhosis, there are increasing data from real-life settings that show acceptable tolerability and satisfying efficacy in terms of response. The data on the administration of locoregional treatments in such patients are also limited, but the overall survival seems to be potentially prolonged when patients are carefully selected, and close adverse event monitoring is applied. The aim of this review is to analyze the existing data regarding the administration of treatments in decompensated patients with HCC, evaluate the effect of therapy on overall survival and highlight the potential risks in terms of tolerability.<\/jats:p>","DOI":"10.3390\/cancers15041310","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T01:36:37Z","timestamp":1676856997000},"page":"1310","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3640-6585","authenticated-orcid":false,"given":"Maria","family":"Tampaki","sequence":"first","affiliation":[{"name":"Academic Department of Gastroenterology, General Hospital of Athens \u201cLaiko\u201d, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3518-4060","authenticated-orcid":false,"given":"George V.","family":"Papatheodoridis","sequence":"additional","affiliation":[{"name":"Academic Department of Gastroenterology, General Hospital of Athens \u201cLaiko\u201d, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3645-582X","authenticated-orcid":false,"given":"Evangelos","family":"Cholongitas","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, General Hospital of Athens \u201cLaiko\u201d, Medical School, National and Kapodistrian University of Athens, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","article-title":"A global view of hepatocellular carcinoma: Trends, risk, prevention and management","volume":"16","author":"Yang","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_2","unstructured":"Global Burden of Disease Cancer Collaboration, Fitzmaurice, C., Abate, D., Abbasi, N., Abbastabar, H., Abd-Allah, F., Abdel-Rahman, O., Abdelalim, A., Abdoli, A., and Abdollahpour, I. (2019). Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived with Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol., 5, 1749."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA A Cancer J Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3322\/caac.21262","article-title":"Global cancer statistics, 2012: Global Cancer Statistics, 2012","volume":"65","author":"Torre","year":"2015","journal-title":"CA A Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.annonc.2021.02.014","article-title":"Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO Clinical Practice Guidelines","volume":"32","author":"Vogel","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_6","unstructured":"European Association for the Study of the Liver (2018). EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J. Hepatol., 69, 182\u2013236."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma: Heimbach","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1097\/MEG.0000000000001481","article-title":"Integrated model for end-stage liver disease maybe superior to some other model for end-stage liver disease-based systems in addition to Child-Turcotte-Pugh and albumin-bilirubin scores in patients with hepatitis B virus-related liver cirrhosis and spontaneous bacterial peritonitis","volume":"31","author":"Chen","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5193028","DOI":"10.1155\/2020\/5193028","article-title":"Assessing the Prognostic Performance of the Child-Pugh, Model for End-Stage Liver Disease, and Albumin-Bilirubin Scores in Patients with Decompensated Cirrhosis: A Large Asian Cohort from Gastroenterology Department","volume":"2020","author":"Wan","year":"2020","journal-title":"Dis. Markers"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/MEG.0b013e3283407158","article-title":"Mortality after surgery in patients with liver cirrhosis: Comparison of Child\u2013Turcotte\u2013Pugh, MELD and MELDNa score","volume":"23","author":"Cho","year":"2011","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cld.1058","article-title":"Systemic Therapy for Hepatocellular Carcinoma","volume":"17","author":"Wang","year":"2021","journal-title":"Clin. Liver Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2021.07.004","article-title":"Systemic treatment of hepatocellular carcinoma: An EASL position paper","volume":"75","author":"Bruix","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1053\/j.gastro.2021.12.276","article-title":"AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma","volume":"162","author":"Su","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"201","DOI":"10.7861\/clinmedicine.15-2-201","article-title":"Management of patients with decompensated cirrhosis","volume":"15","author":"Harrison","year":"2015","journal-title":"Clin. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000368152","article-title":"Treatment of Hepatocellular Carcinoma with Child-Pugh C Cirrhosis","volume":"87","author":"Nouso","year":"2014","journal-title":"Oncology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40364-021-00350-4","article-title":"Recent advances in systemic therapy for hepatocellular carcinoma","volume":"10","author":"Zhang","year":"2022","journal-title":"Biomark Res."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Pelizzaro, F., Ramadori, G., and Farinati, F. (2022, November 06). Systemic Therapies for Hepatocellular Carcinoma: An Evolving Landscape. HR.2021. Available online: https:\/\/hrjournal.net\/article\/view\/4021.","DOI":"10.20517\/2394-5079.2021.24"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"17018","DOI":"10.1038\/s41598-022-21528-2","article-title":"Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma","volume":"12","author":"Shimose","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_19","first-page":"212","article-title":"Systemic therapy in advanced-stage hepatocellular carcinoma","volume":"13","author":"Graziadei","year":"2020","journal-title":"Memo-Mag. Eur. Med. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4152","DOI":"10.3748\/wjg.v24.i36.4152","article-title":"Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and\/or prognostic markers?","volume":"24","author":"Marisi","year":"2018","journal-title":"WJG"},{"key":"ref_21","unstructured":"(2014, June 18). \u201cNexavar EPAR\u201d. European Medicines Agency (EMA). Archived from the original on 14 October 2021. Retrieved 18 September 2022. Available online: www.ema.europa.eu\/en\/medicines\/human\/EPAR\/nexavar."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in Advanced Hepatocellular Carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/ijcp.12352","article-title":"GIDEON (Global Investigation of therapeutic DE cisions in hepatocellular carcinoma and Of its treatment with sorafeNib): Second interim analysis","volume":"68","author":"Lencioni","year":"2014","journal-title":"Int. J. Clin. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3109\/00365521.2012.683040","article-title":"Clinical course of sorafenib treatment in patients with hepatocellular carcinoma","volume":"47","author":"Woo","year":"2012","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1007\/s10637-018-0621-x","article-title":"Survival and tolerance to sorafenib in Child-Pugh B patients with hepatocellular carcinoma: A prospective study","volume":"36","author":"Leal","year":"2018","journal-title":"Investig. New Drugs"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2018.09.031","article-title":"Sorafenib as first-line therapy in patients with advanced Child-Pugh B hepatocellular carcinoma\u2014A meta-analysis","volume":"105","author":"McNamara","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"175883592211166","DOI":"10.1177\/17588359221116608","article-title":"Lenvatinib in patients with unresectable hepatocellular carcinoma who progressed to Child-Pugh B liver function","volume":"14","author":"Huynh","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2147\/CEG.S256691","article-title":"Safety and Efficacy of Lenvatinib Treatment in Child\u2013Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis","volume":"13","author":"Ogushi","year":"2020","journal-title":"CEG"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Park, M.K., Lee, Y.B., Moon, H., Choi, N.R., Kim, M.A., Jang, H., Nam, J.Y., Cho, E.J., Lee, J.H., and Yu, S.J. (2022). Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation. Dig. Dis. Sci., Available online: https:\/\/link.springer.com\/10.1007\/s10620-021-07365-9.","DOI":"10.1007\/s10620-021-07365-9"},{"key":"ref_31","first-page":"2759","article-title":"REAL-WORLD effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice","volume":"17","author":"Singal","year":"2021","journal-title":"Cancer Rep."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tsuchiya, K., Kurosaki, M., Sakamoto, A., Marusawa, H., Kojima, Y., Hasebe, C., Arai, H., Joko, K., Kondo, M., and Tsuji, K. (2021). The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study. Cancers, 13.","DOI":"10.3390\/cancers13112608"},{"key":"ref_33","first-page":"247","article-title":"Lenvatinib as First-line Treatment of Hepatocellular Carcinoma in Patients with Impaired Liver Function in Advanced Liver Cirrhosis: Real World Data and Experience of a Tertiary Hepatobiliary Center","volume":"30","author":"Cosma","year":"2021","journal-title":"J. Gastrointest. Liver Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1056\/NEJMoa1717002","article-title":"Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma","volume":"379","author":"Meyer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"El-Khoueiry, A.B., Meyer, T., Cheng, A.L., Rimassa, L., Sen, S., Milwee, S., Kelley, R.K., and Abou-Alfa, G.K. (2022). Safety and efficacy of cabozantinib for patients with advanced hepatocellular carcinoma who advanced to Child\u2013Pugh B liver function at study week 8: A retrospective analysis of the CELESTIAL randomised controlled trial. BMC Cancer, 22.","DOI":"10.1186\/s12885-022-09453-z"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/s41416-021-01532-5","article-title":"Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade","volume":"26","author":"Kelley","year":"2022","journal-title":"Br. J. Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"175883592210979","DOI":"10.1177\/17588359221097934","article-title":"Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: A multicenter retrospective analysis","volume":"14","author":"Bang","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1159\/000515490","article-title":"Cabozantinib in Advanced Hepatocellular Carcinoma: Efficacy and Safety Data from an International Multicenter Real-Life Cohort","volume":"10","author":"Finkelmeier","year":"2021","journal-title":"Liver Cancer"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jhep.2021.04.047","article-title":"CheckMate 040 cohort 5: A phase I\/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"75","author":"Kudo","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_42","first-page":"189","article-title":"Comparison of nivolumab and sorafenib for first systemic therapy in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis","volume":"1","author":"Chapin","year":"2022","journal-title":"Cancer Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Choi, W.M., Lee, D., Shim, J.H., Kim, K.M., Lim, Y.S., Lee, H.C., Yoo, C., Park, S.R., Ryu, M.H., and Ryoo, B.Y. (2020). Effectiveness and Safety of Nivolumab in Child\u2013Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. Cancers, 12.","DOI":"10.3390\/cancers12071968"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1111\/apt.15245","article-title":"Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicentre real-world cohort","volume":"49","author":"Scheiner","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_46","first-page":"1000","article-title":"Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study","volume":"4","author":"Fulgenzi","year":"2022","journal-title":"Hepatology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1007\/s12072-022-10392-x","article-title":"Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment","volume":"16","author":"Chen","year":"2022","journal-title":"Hepatol. Int."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Persano, M., Rimini, M., Tada, T., Suda, G., Shimose, S., Kudo, M., Cheon, J., Finkelmeier, F., Lim, H.Y., and Rimassa, L. (2022). Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: A multicenter real-world study. J. Cancer Res. Clin. Oncol. J., ahead of print.","DOI":"10.1007\/s00432-022-04512-1"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"175883592210802","DOI":"10.1177\/17588359221080298","article-title":"Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: A real-world experience","volume":"14","author":"Jochheim","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_50","first-page":"EVIDoa2100070","article-title":"Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma","volume":"1","author":"Lau","year":"2022","journal-title":"NEJM"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.dld.2013.03.002","article-title":"Treatment of hepatocellular carcinoma in Child-Pugh B patients","volume":"45","author":"Piscaglia","year":"2013","journal-title":"Dig. Liver Dis."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6555","DOI":"10.2147\/OTT.S170836","article-title":"Radiofrequency Ablation of hepatocellular carcinoma: A meta-analysis of overall survival and recurrence-free survival","volume":"11","author":"CasadeiGardini","year":"2018","journal-title":"OTT"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2214\/AJR.04.1266","article-title":"Radiofrequency Ablation of Hepatocellular Carcinoma in Patients with Decompensated Cirrhosis: Evaluation of Therapeutic Efficacy and Safety","volume":"186","author":"Kim","year":"2006","journal-title":"Am. J. Roentgenol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bjc.6604282","article-title":"Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis","volume":"98","author":"Nouso","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1159\/000355259","article-title":"Hepatocellular Carcinoma in Child-Pugh C Cirrhosis: Prognostic Factors and Survival Benefit of Nontransplant Treatments","volume":"31","author":"Kudo","year":"2013","journal-title":"Dig. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/lt.23552","article-title":"Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic hepatic dysfunction: High-Risk Transarterial Chemoembolization Outcomes","volume":"19","author":"Garwood","year":"2013","journal-title":"Liver Transpl."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Miksad, R.A., Ogasawara, S., Xia, F., Fellous, M., and Piscaglia, F. (2019). Liver function changes after transarterial chemoembolization in US hepatocellular carcinoma patients: The LiverT study. BMC Cancer, 19.","DOI":"10.1186\/s12885-019-5989-2"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jhep.2019.01.013","article-title":"Development of a prognostic score for recommended TACE candidates with hepatocellular carcinoma: A multicentre observational study","volume":"70","author":"Wang","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_59","first-page":"S1499387222000157","article-title":"ASARA, a prediction model based on Child-Pugh class in hepatocellular carcinoma patients undergoing transarterial chemoembolization","volume":"22","author":"Jia","year":"2022","journal-title":"Hepatobiliary Pancreat. Dis. Int."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/j.jhep.2011.10.021","article-title":"Superselectivetransarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines","volume":"56","author":"Takayasu","year":"2012","journal-title":"J. Hepatol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/hpb.12194","article-title":"Chemoembolization outcomes for hepatocellular carcinoma in cirrhotic patients with compromised liver function","volume":"16","author":"Dorn","year":"2014","journal-title":"HPB"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1159\/000367765","article-title":"Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis","volume":"5","author":"Kitai","year":"2016","journal-title":"Liver Cancer"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6518","DOI":"10.3748\/wjg.v21.i21.6518","article-title":"Transarterial radioembolization for hepatocellular carcinoma: An update and perspectives","volume":"21","author":"Sacco","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/cld.908","article-title":"Position 2: Transarterial Radioembolization Should Be the Primary Locoregional Therapy for Unresectable Hepatocellular Carcinoma","volume":"15","author":"Rahman","year":"2020","journal-title":"Clin. Liver Dis. (Hoboken)"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Cho, Y.Y., Lee, M., Kim, H.C., Chung, J.W., Kim, Y.H., Gwak, G.Y., Bae, S.H., do Kim, Y., Heo, J., and Kim, Y.J. (2016). Radioembolization Is a Safe and Effective Treatment for Hepatocellular Carcinoma with Portal Vein Thrombosis: A Propensity Score Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0154986"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00270-020-02434-4","article-title":"Yttrium-90 Radioembolization for BCLC Stage C Hepatocellular Carcinoma Comparing Child-Pugh A Versus B7 Patients: Are the Outcomes Equivalent?","volume":"43","author":"Zu","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2967\/jnumed.117.199752","article-title":"90Y Radioembolization for Locally Advanced Hepatocellular Carcinoma with Portal Vein Thrombosis: Long-Term Outcomes in a 185-Patient Cohort","volume":"59","author":"Abouchaleh","year":"2018","journal-title":"J. Nucl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jhep.2012.09.003","article-title":"Radioembolization for hepatocellular carcinoma with portal vein thrombosis: Impact of liver function on systemic treatment options at disease progression","volume":"58","author":"Memon","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/SLA.0000000000000821","article-title":"A Comparison of the Surgical Outcomes Among Patients With HBV-positive, HCV-positive, and Non-B Non-C Hepatocellular Carcinoma: A Nationwide Study of 11,950 Patients","volume":"261","author":"Utsunomiya","year":"2015","journal-title":"Ann. Surg."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s11605-018-3690-4","article-title":"Liver Transplantation and Liver Resection for Cirrhotic Patients with Hepatocellular Carcinoma: Comparison of Long-Term Survivals","volume":"22","author":"Krenzien","year":"2018","journal-title":"J. Gastrointest. Surg."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5582\/bst.2021.01094","article-title":"Surgical treatment of hepatocellular carcinoma","volume":"15","author":"Sugawara","year":"2021","journal-title":"BST"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S0016-5085(96)70070-7","article-title":"Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure","volume":"111","author":"Bruix","year":"1996","journal-title":"Gastroenterology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"100190","DOI":"10.1016\/j.jhepr.2020.100190","article-title":"Liver resection for hepatocellular carcinoma in patients with clinically significant portal hypertension","volume":"3","author":"Azoulay","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Leyh, C., Heucke, N., Schotten, C., B\u00fcchter, M., Bechmann, L.P., Wichert, M., Dech\u00eane, A., Herrmann, K., Heider, D., and Sydor, S. (2022). LiMAx Prior to Radioembolization for Hepatocellular Carcinoma as an Additional Tool for Patient Selection in Patients with Liver Cirrhosis. Cancers, 14.","DOI":"10.3390\/cancers14194584"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1001\/jamasurg.2016.1121","article-title":"Hierarchic Interaction of Factors Associated With Liver Decompensation After Resection for Hepatocellular Carcinoma","volume":"15","author":"Citterio","year":"2016","journal-title":"JAMA Surg."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.jhep.2015.04.005","article-title":"Laparoscopic versus open liver resection for hepatocellular carcinoma: Case-matched study with propensity score matching","volume":"63","author":"Han","year":"2015","journal-title":"J. Hepatol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00464-019-06774-2","article-title":"A systematic review and meta-analysis comparing the short- and long-term outcomes for laparoscopic and open liver resections for liver metastases from colorectal cancer","volume":"34","author":"Ciria","year":"2020","journal-title":"Surg. Endosc."},{"key":"ref_79","first-page":"182","article-title":"Controversies in criteria for liver transplantation in hepatocellular carcinoma","volume":"32","author":"Parikh","year":"2016","journal-title":"Curr. Opin. Gastroenterol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"36","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1002\/lt.25419","article-title":"Liver Transplantation in France","volume":"25","author":"Durand","year":"2019","journal-title":"Liver Transpl."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1053\/jlts.2002.34923","article-title":"Liver transplantation for hepatocellular carcinoma: Analysis of survival according to the intention-to-treat principle and dropout from the waiting list","volume":"8","author":"Yao","year":"2002","journal-title":"Liver Transplant."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Crocetti, L., Bozzi, E., Scalise, P., Bargellini, I., Lorenzoni, G., Ghinolfi, D., Campani, D., Balzano, E., De Simone, P., and Cioni, R. (2021). Locoregional Treatments for Bridging and Downstaging HCC to Liver Transplantation. Cancers, 13.","DOI":"10.3390\/cancers13215558"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"134","DOI":"10.21037\/hbsn.2018.01.07","article-title":"Locoregional therapy as a bridge to liver transplantation for hepatocellular carcinoma within Milan criteria: From a transplant oncology viewpoint","volume":"7","author":"Hibi","year":"2018","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"863086","DOI":"10.3389\/frtra.2022.863086","article-title":"Neoadjuvant Therapy With Cabozantinib as a Bridge to Liver Transplantation in Patients With Hepatocellular Carcinoma (HCC): A Case Report","volume":"1","author":"Bhardwaj","year":"2022","journal-title":"Front Transplant."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.21037\/tgh.2017.09.01","article-title":"Bridging patients with hepatocellular cancer waiting for liver transplant: All the patients are the same?","volume":"2","author":"Coletta","year":"2017","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1111\/ajt.16965","article-title":"Liver transplantation for hepatocellular carcinoma following checkpoint inhibitor therapy with nivolumab","volume":"22","author":"Schnickel","year":"2022","journal-title":"Am. J Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.3748\/wjg.v25.i21.2591","article-title":"Liver transplantation for hepatocellular carcinoma: Where do we stand?","volume":"25","author":"Santopaolo","year":"2019","journal-title":"WJG"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jceh.2014.03.049","article-title":"Role of Supportive Care for Terminal Stage Hepatocellular Carcinoma","volume":"4","author":"Kumar","year":"2014","journal-title":"J. Clin. Exp. Hepatol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.clinthera.2018.02.017","article-title":"Palliative Care for People With Hepatocellular Carcinoma, and Specific Benefits for Older Adults","volume":"40","author":"Woodrell","year":"2018","journal-title":"Clin. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","article-title":"Child\u2013Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies","volume":"95","author":"Peng","year":"2016","journal-title":"Medicine"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100620","DOI":"10.1016\/j.jhepr.2022.100620","article-title":"Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma","volume":"5","author":"Scheiner","year":"2022","journal-title":"JHEP Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1310\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:36:11Z","timestamp":1760121371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/15\/4\/1310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,18]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["cancers15041310"],"URL":"https:\/\/doi.org\/10.3390\/cancers15041310","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,18]]}}}